Subscribe to Newsletter
Diagnostics Genetics and epigenetics, COVID-19, Neurology, Technology and innovation

Research Roundup

The cold truth


A genome wide association study for Raynaud’s phenomenon (RP) – a vasospastic disorder that affects the hands and feet – has identified DRA2A and IRX1 as candidate causal genes that predispose individuals to the disease. This finding highlights RP as a disease with complex genetic architecture rather than a cold-induced phenomenon (1).

Brain burden


Many studies have supported a connection between viral infections and an increased risk of neurodegeneration. New research indicates that the neurological effects of COVID-19 could possibly lead to Alzheimer’s disease (AD) or exacerbate existing AD pathologies through inflammatory processes. The paper concludes that the synergistic effect of the interaction of these diseases needs to be explored in more detail (2).

The scores on the doors…


A recent study has found that polygenic risk scores perform poorly in population screening, individual risk prediction, and population risk stratification. The team reviewed 926 polygenic scores for 310 common diseases, finding that five percent of people who do not develop the disease test positive and only 11 percent of individuals who actually develop the disease are identified (3). 

Probing proteins


Using cryo-electron microscopy, researchers have analyzed the structure of two proteins heavily involved with immune response –  C3aR and C5aR1. The images provided detailed insight into the molecular mechanisms of ligand binding, how the receptors change shape when activated, and how they interact with different molecules (4). 

Take your vitamins!


Researchers have explored the connection between vitamin B12 and inflammation – and found that individuals with higher serum levels of vitamin B12 had lower concentrations of the inflammatory markers IL-6 and CRP (5). They hope to explore the potential role of B12 in disease management.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. S Hartmann et al., Nat Commun, 14 (2023). PMID: 37828025.
  2. S Furman et al., J Neurochem [Online ahead of print] (2023). PMID: 37850241.
  3. A D Hingoran et al., BMJ Med, 2 (2023). PMID: 37859783.
  4. M K Yadav et al., Cell, 186, 4956 (2023). PMID: 37852260.
  5. I Domínguez-López et al., J Sci Food Agric [Online ahead of print] (2023). PMID: 37690097.
About the Author
Georgia Hulme

Associate Editor for the Pathologist

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register